Morgan Stanley raised price targets and ratings for Ultragenyx Pharmaceutical.
9 reports, 1 independent
Updated Sep 23
Gone quiet
- Reports
- 9
- Developments
- 1
- Repetition
- 89%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley raised price targets and ratings for Ultragenyx Pharmaceutical.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
Related events
- Morgan Stanley and Carlyle Group released research reports and price targets for a company whose stock trades on the Nasdaq platform.
- Morgan Stanley raised its price target on Vita Coco, with Benzinga and MarketBeat also providing ratings.
- Benzinga reports on Compass stock analysis, including Morgan Stanley raising its price target and CEO Robert Reffkin selling company stock.
- Albemarle Corporation reported earnings and revenue beats amid predictions of high lithium demand, leading to analyst downgrades.
- Morgan Stanley and Bank of America raised price targets on NetApp shares, with MarketBeat reporting the consensus rating.